Clinical Trial Record

Return to Clinical Trials

Pancreatic Cancer Recurrence in the Netherlands


2014-01-01


2023-07-01


2023-07-01


1750

Study Overview

Pancreatic Cancer Recurrence in the Netherlands

The aim of this nationwide, observational cohort study is to evaluate current surveillance strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the Netherlands, with regard to the detection, treatment and survival of PDAC recurrence.

N/A

  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer
  • Pancreas Cancer
  • PDAC
    • 18-036/C

    Study Record Dates

    These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

    Study Registration Dates Results Reporting Dates Study Record Updates

    2020-10-15  

    N/A  

    2023-02-01  

    2020-10-24  

    N/A  

    2023-02-02  

    2020-10-27  

    N/A  

    2023-02  

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    Design Details

    Primary Purpose:
    N/A


    Allocation:
    N/A


    Interventional Model:
    N/A


    Masking:
    N/A


    Arms and Interventions

    Participant Group/ArmIntervention/Treatment
    Primary Outcome MeasuresMeasure DescriptionTime Frame
    Incidence of PDAC recurrenceIncidence of PDAC recurrence within the Netherlands; PDAC recurrence is either pathologically proven, or suspected through cross-sectional imaging, preferably confirmed by consensus during a multidisciplinary meeting.Within a follow-up period up to 5 years
    Patterns of PDAC recurrence* Asymptomatic vs. symptomatic: Symptomatic recurrence is defined as the presence of symptoms suggestive for PDAC recurrence at recurrence diagnosis. If PDAC recurrence is detected in absence of suspected symptoms, disease recurrence was defined as asymptomatic. * First site of recurrence: isolated local recurrence, liver-only, lung-only, multiple-site, other isolated distant * Early vs. late recurrence: disease-free survival ≥12 months vs. <12 monthsWithin a follow-up period up to 5 years
    Treatment of PDAC recurrenceEither systemic and/or local treatment or best-supportive-careWithin a follow-up period up to 5 years
    SurvivalOverall survival (from the time of resection), disease-free survival (from the time of resection), post-recurrence survival (from the time of recurrence diagnosis)Within a follow-up period up to 5 years
    Secondary Outcome MeasuresMeasure DescriptionTime Frame
    Presence of symptoms at time of (suspected) recurrenceWhich symptoms are associated with PDAC recurrence?Within a follow-up period up to 5 years
    Performance score at time of recurrence detectionWhat is the ECOG performance score of patients at time of recurrence diagnosis?Within a follow-up period up to 5 years
    Use of imaging procedures during follow-upHow much imaging procedures are performed during postoperative follow-up for the detection of PDAC recurrence? Are these procedures routinely performed?Within a follow-up period up to 5 years
    Number of histologically confirmed recurrencesHow often is PDAC recurrence histologically confirmed?Within a follow-up period up to 5 years

    Contacts and Locations

    This section provides the contact details for those conducting the study, and information on where this study is being conducted.

    Study Contact

    Name: Iris van Goor, MD

    Phone Number: +31631917882

    Email: I.W.J.vanGoor-5@umcutrecht.nl

    Study Contact Backup

    Name: Lois Daamen, MD

    Phone Number: +31651223276

    Email: L.A.Daamen-3@umcutrecht.nl

    Participation Criteria

    Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

    Ages Eligible for Study:
    ALL

    Sexes Eligible for Study:

    Accepts Healthy Volunteers:

      Inclusion Criteria:

    • Patients undergoing a pancreatic resection (PPPD, Whipple, distal pancreatectomy or total pancreatectomy) for histologically proven PDAC in one of the 16 Dutch centers for pancreatic surgery

    • Exclusion Criteria:

    • Patients with 30-day postoperative mortality

    Collaborators and Investigators

    This is where you will find people and organizations involved with this study.

    • Amsterdam UMC, location VUmc
    • Erasmus Medical Center
    • Catharina Ziekenhuis Eindhoven
    • Radboud University Medical Center
    • University Medical Center Groningen
    • Jeroen Bosch Ziekenhuis
    • Leiden University Medical Center
    • Maastricht University Medical Center
    • Maasstad Hospital
    • Amphia Hospital
    • Onze Lieve Vrouwe Gasthuis
    • Reinier de Graaf Groep
    • Isala
    • St. Antonius Hospital

    • PRINCIPAL_INVESTIGATOR: I. Quintus Molenaar, MD, PhD, UMC Utrecht

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available